Granules India Management Guidance Tracker

Management expects meaningful improvement in Q4 performance, with the business reaching EBITDA breakeven in the current quarter.

Company will submit requested documentation to FDA shortly after the January meeting; no timeline for reinspection given.

The company expects to keep net working capital at around 33% of sales in FY27, despite cost escalations.

Remediation activities are complete; the company is ready for FDA reinspection at any time, with nine product applications awaiting clearance.

At least one or two existing products will be launched from GLS to cater to additional demand, with incremental revenue expected.

Management aspires to continue adding $40-50 million annually to US revenue, consistent with recent trends.

Management targets annual PAT-positive performance for the peptide CDMO business in FY27, despite quarterly variations.

Capital expenditure expected around ₹600 crore, including ₹200 crore for a new distribution center in the US and investments in API facility and IT.